To include your compound in the COVID-19 Resource Center, submit it here.

Synergix: Searching with software

Synergix Inc. sees the dilemma of genome-driven target overload as an opportunity to apply its rational drug design technology to rapidly create and optimize leads in a cost-effective manner.

Founded in 1996, Synergix evolved out of the work of founder and CEO Claude Cohen, who honed the technology for molecular modeling and drug design at Hoechst-Roussel-Uclaf-Marion and Ciba-Geigy Ltd., now Aventis

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers